Category: WFN1 Contributors

1234521530 / 2150 POSTS
By Lisa Thompson NASDAQ:NETE READ THE FULL NETE RESEARCH REPORT Shareholders of Net Element (NASDAQ:NETE) have approved the merger with Mullen Technologies and we expect the deal to close shortly. A capital raise is the final condition for the merger ...
When engagement increases, so do sales.If after the initial contact you lose sight of the plan, you could lose everything. And you can’t afford that. Cultivating a relationship with a prospect involves time and effort. But there are some simpl ...
By M. Marin NASDAQ:VQS | TSX:VQS.V READ THE FULL VQS RESEARCH REPORT Backlog reached record levels… VIQ Solutions’ (NASDAQ:VQS) (TSX:VQS.V) backlog has reached record levels, reflecting growing demand from existing and new customers and some revenue ...
By David Bautz, PhD NASDAQ:QLGN READ THE FULL QLGN RESEARCH REPORT Financial Update On August 17, 2021, Qualigen Therapeutics, Inc. (NASDAQ:QLGN) announced financial results for the second quarter of 2021. The company reported $1.1 million in revenue ...
By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT LiFT Liver Biopsy Results On August 25th, 2021 Lipocine (NASDAQ:LPCN) released liver biopsy results for its Phase II LiFT study in NASH. LiFT, or Liver Fat Intervention with Ora ...
By M. Marin NASDAQ:ELYS READ THE FULL ELYS RESEARCH REPORT 1H21 Turnover up significantly Elys Game Technology (NASDAQ:ELYS) reported 2Q21 results last week. Year-to-date, the company has recorded record turnover – or betting handle – of $463.3 milli ...
By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Phase 3 DISRUPT Trial Continues ContraFect, Inc. (NASDAQ:CFRX) is currently conducting the Phase 3 DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) tria ...
By Ann Heffron, CFA, CPA OTC:CPKF READ THE FULL CPKF RESEARCH REPORT CPKF’s (OTC:CPKF) second quarter net earnings jumped $1.9 million, or 93%, year over year to $4.0 million, while 2021’s second quarter diluted EPS soared by $0.40, or 96%, to $0.82 ...
By David Bautz, PhD OTC:ATBPF | TSX:ATE.TO READ THE FULL ATE.TO RESEARCH REPORT Business Update Phase 3 Program for Otenaproxesul on Pause On August 3, 2021, Antibe Therapeutics, Inc. (TSX:ATE.TO) (OTC:ATBPF) announced that the absorption, metabolism ...
By Lisa Thompson NASDAQ:UCL READ THE FULL UCL RESEARCH REPORT UCloudlink (NASDAQ:UCL) exceeded the high end of its revenue guidance for Q2 2021 of between $18-19 million coming in at $19.2 million, but gave Q3 guidance of between $19.3-20.0 million, ...
1234521530 / 2150 POSTS